BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20181407)

  • 1. Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy.
    Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
    Lung Cancer; 2010 Nov; 70(2):211-7. PubMed ID: 20181407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer.
    van der Drift MA; Hol BE; Klaassen CH; Prinsen CF; van Aarssen YA; Donders R; van der Stappen JW; Dekhuijzen PN; van der Heijden HF; Thunnissen FB
    Lung Cancer; 2010 May; 68(2):283-7. PubMed ID: 19632736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of utility of plasma TNF-alpha level in predicting therapeutic efficacy in patients with advanced non-small cell lung cancer.
    Kumar S; Guleria R; Singh V; Mohan A; Bharti AC; Das BC
    Cytokine; 2010 Sep; 51(3):245-8. PubMed ID: 20599393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.
    Gautschi O; Bigosch C; Huegli B; Jermann M; Marx A; Chassé E; Ratschiller D; Weder W; Joerger M; Betticher DC; Stahel RA; Ziegler A
    J Clin Oncol; 2004 Oct; 22(20):4157-64. PubMed ID: 15483026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes.
    Sher YP; Shih JY; Yang PC; Roffler SR; Chu YW; Wu CW; Yu CL; Peck K
    Clin Cancer Res; 2005 Jan; 11(1):173-9. PubMed ID: 15671543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
    Paci M; Maramotti S; Bellesia E; Formisano D; Albertazzi L; Ricchetti T; Ferrari G; Annessi V; Lasagni D; Carbonelli C; De Franco S; Brini M; Sgarbi G; Lodi R
    Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of plasma tumour necrosis factor-alpha and transforming growth factor-beta1 as predictors of survival and treatment outcome in advanced non-small cell lung carcinoma.
    Kumar S; Guleria R; Mohan A; Singh V; Ali A; Bharti AC; Das BC
    Biomarkers; 2010 Aug; 15(5):446-53. PubMed ID: 20486867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?
    Camps C; Sirera R; Bremnes R; Blasco A; Sancho E; Bayo P; Safont MJ; Sánchez JJ; Tarón M; Rosell R
    Lung Cancer; 2005 Dec; 50(3):339-46. PubMed ID: 16139926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.
    Kasahara K; Arao T; Sakai K; Matsumoto K; Sakai A; Kimura H; Sone T; Horiike A; Nishio M; Ohira T; Ikeda N; Yamanaka T; Saijo N; Nishio K
    Clin Cancer Res; 2010 Sep; 16(18):4616-24. PubMed ID: 20679350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High plasma D-dimer level is associated with decreased survival in patients with lung cancer.
    Altiay G; Ciftci A; Demir M; Kocak Z; Sut N; Tabakoglu E; Hatipoglu ON; Caglar T
    Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):494-8. PubMed ID: 17513096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of therapeutic outcome in non-small cell lung cancer and DNA damage assayed by polymerase chain reaction in leukocytes damaged in vitro.
    Oshita F; Yamamoto N; Fukuda M; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
    Cancer Res; 1995 Jun; 55(11):2334-7. PubMed ID: 7757984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of plasma TGF-β1 level in predicting therapeutic efficacy and prognosis in patients with advanced non-small cell lung cancer.
    Kumar S; Guleria R; Mohan A; Singh V; Bharti AC; Das BC
    Cancer Invest; 2011 Mar; 29(3):202-7. PubMed ID: 21280981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of K-Ras mutations in non-small cell lung cancer: still an issue for open debate.
    Neri M; Cesario A; Granone P; Dominioni L; Puntoni R; D'Angelillo RM; Russo P
    Lung Cancer; 2006 Sep; 53(3):393-5; author reply 397-8. PubMed ID: 16887233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer.
    Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
    Eur Respir J; 2010 Oct; 36(4):885-92. PubMed ID: 20185420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of free circulating DNA as a diagnostic marker in lung cancer.
    Sozzi G; Conte D; Leon M; Ciricione R; Roz L; Ratcliffe C; Roz E; Cirenei N; Bellomi M; Pelosi G; Pierotti MA; Pastorino U
    J Clin Oncol; 2003 Nov; 21(21):3902-8. PubMed ID: 14507943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer?
    Maione P; Rossi A; Di Maio M; Gridelli C
    Lung Cancer; 2009 Oct; 66(1):8-14. PubMed ID: 19328587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer.
    Graziano SL; Tatum AH; Gonchoroff NJ; Newman NB; Kohman LJ
    Clin Cancer Res; 1997 Jan; 3(1):87-93. PubMed ID: 9815542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer.
    De Petris L; Brandén E; Herrmann R; Sanchez BC; Koyi H; Linderholm B; Lewensohn R; Linder S; Lehtiö J
    Eur J Cancer; 2011 Jan; 47(1):131-7. PubMed ID: 20822898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of the prognostic role of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer.
    Sirera R; Gil M; Blasco A; Cabrera A; Safont MJ; Iranzo V; Cayuela D; Rosell R; Camps C
    Lung Cancer; 2008 Jul; 61(1):104-8. PubMed ID: 18243403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aberrant methylation of circulating DNA for prediction of chemo-sensitivity of non-small cell lung cancer].
    Takai D
    Gan To Kagaku Ryoho; 2010 Feb; 37(2):189-93. PubMed ID: 20154471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.